



Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 3<sup>rd</sup> October 2019  
Ein Cyf / Our Ref: 19-I-002

01639 648363  
FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 6<sup>th</sup> September 2019. Your request sought information relating to breast cancer.

**1a. Does your health board treat advanced breast cancer?**

Yes

**1b. If none, where are your patients referred?**

Not applicable

**2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;**

<b>HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]</b>	
<b>HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]</b>	
<b>HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]</b>	
<b>HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease</b>	
<b>Not Known</b>	

The number of patients with advanced breast cancer currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly



exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**3. In the past 3 months, how many breast cancer patients were treated with:**

<b>Abemaciclib (Verzenios) + aromatase inhibitor *</b>	Nil
<b>Abemaciclib (Verzenios) + Fulvestrant (Faslodex)</b>	5
<b>Alpelisib (Piqray) + Fulvestrant (Faslodex)</b>	Nil
<b>Atezolizumab (Tecentriq)**</b>	Nil
<b>Bevacizumab (Avastin)</b>	Nil
<b>Eribulin (Halaven)</b>	<5
<b>Everolimus (Afinitor) + Exemestane</b>	<5
<b>Fulvestrant (Faslodex) as a single agent</b>	9
<b>Gemcitabine + paclitaxel</b>	Nil
<b>Lapatinib (Tyverb)</b>	Nil
<b>Neratinib (Nerlynx)</b>	Nil
<b>Olaparib (Lynparza)</b>	Nil
<b>Palbociclib (Ibrance) + aromatase inhibitor*</b>	Nil
<b>Pertuzumab (Perjeta) + trastuzumab + docetaxel</b>	<5
<b>Ribociclib (Kisqali) + aromatase inhibitor*</b>	<5
<b>Ribociclib (Kisqali) + Fulvestrant (Faslodex)</b>	Nil
<b>Talazoparib (Talzenna)</b>	Nil
<b>Trastuzumab + paclitaxel</b>	Nil
<b>Trastuzumab as a single agent</b>	24
<b>Trastuzumab emtansine (Kadcyla)</b>	<5
<b>Other active systemic anti-cancer therapy **</b>	25

**\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

**\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent**

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office



(Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

